Innovative products for chronic breathing ailments
Products for chronic breathing ailments
environmental conditions prevent man from breathing freely. Innovators are seen turning their attention to the increasing Copd cases to invent innovative products and solutions.
Chronic respiratory diseases that affect the airways and different structures of the lungs are on the rise. As per an article in the journal Office of Disease Prevention and Health Promotion, prevalence of asthma has been increasing since 1980. Furthermore, Chronic Obstructive Pulmonary Disease (COPD) is believed to be the fourth main cause of death in North America. In 2006, about 1,20,000 people succumbed to COPD in the United States. This figure was close to the number of patients who lost their battle against lung cancer. Last year, Jackson, Mississippi was declared as the “Allergy Capital” of the United States by experts in “Asthma and Allergy Foundation of America”. Researchers at Allied Market Research analysing the share, size and growth in the COPD and asthma devices market say concerns over air pollution will open new avenues for the industry.
Important priorities to enhance early diagnosis
Big brands bank on billion dollar inhaler industry A major announcement in the inhaler industry arrived when Elder Pharmaceuticals Limited revealed that it is banking on the Rs 800 crore nasal inhaler category in India. This pharma company plans on strengthening its rural marketing plans and selling products through a strong distribution channel. Reduced price points as well as attractive packaging are believed to be some of the areas where inhaler manufacturers would be focusing more.
A company named Teva made waves in the COPD and
asthma devices market when it announced that the Food and Drug Association has finally accepted to review the manufacturer’s new drug applications for two new products. The first, a salmeterol product, is Teva’s fixeddose combination ICS and LABA, which are delivered through the company’s RespiClick breath-actuated, MDPI. Another fluticasone propionate, which is an ICS monotherapy delivered through the RespiClick device, has also caught quite some attention.
New prototype nebuliser would soon replace injections
Nebulisers are not new. Medical practitioners have been using bulky and big electric nebulisers for the past 25 years to help kids’ breathe without difficulty during an asthma attack. However, an advanced prototype nebuliser developed in 2015 at the famous RMIT, Melbourne, has revolutionised the COPD and asthma devices market. Designed to easily fit into a human hand, the device can deliver a higher dose of drugs per minute than the current nebulisers available in the market. Product developers behind this advanced device said that the product will soon replace the injections as well as traditional inhalers for patients with conditions such as diabetes, cancer, asthma and cystic fibrosis. The product developers further add that it is too early to say what the price of the product will be, but they hope it to be priced below USD50. Ideally, with the new version that’s affordable enough, their demand in developing nations such as India, Africa and others, where diseases are often spread through reuse of nonsterilised needles, would increase.
r&D in drug powder inhalers strengthens
Pulmonary as well as nasal delivery is a rapidly growing field. Growth in this segment is particularly driven by the dominance of several chronic obstructive diseases, particularly in developing countries such as India, Africa and others. Furthermore, the dry powder inhaler technology that uses engineered particles has also become the most preferred approach, when it comes to inhalation formulation, over other aerosols as well as dry-powder technologies.
A company named “Capsugel’s Dosage Form Solutions” shot to fame when it made a huge investment in two important components required to administer an inhalation dosage form for its end-users. The company’s inhalation formulation as well as process design applies a particle – engineering production platform. Another attraction is the manufacturer’s full range of engineered dry powder inhaler capsule. Capsugel’s product is in its Phase 3 clinical manufacturing scales. They are also operating with equipment makers to design finished equipment as well as further optimise the solution. Such products will create new opportunities for many COPD
and asthma devices market players.
Metered dose inhalers segment witnesses B2B deals
The metered dose inhaler segment has seen major business to business deals. Propeller Health partnered with Aptar Pharma, a global drug delivery systems provider. Under the terms of the agreement, Propeller and Aptar will jointly develop the world’s first digital, connected metered dose inhaler with an integrated sensor and a novel electronic dose counter. The device is currently available for licensing and is expected to enter clinical studies later this year. Propeller Health also announced new commercial partnerships with Humana, whose employees are participating in the AIR Louisville programme, and with AMC Health, which will use Propeller to power its care management programmes for complex COPD patients. The investor took this bold step to become the first to the market connected, integrated metered dose inhaler company. Commenting on the recent development, David Van Sickle, the Chief Executive Officer at the Propeller, said “Patients and physicians deserve better designed inhalers that are easier to use and that help them successfully treat their chronic respiratory disease.” Sickle further explained, “We are excited to work with Aptar to bring important digital innovation to respiratory drug delivery. We expect our connected inhaler to become the cornerstone for a platform of digital programs that will support and encourage better management of and quality of life with chronic respiratory disease. Together I believe we have the scale and expertise to impact millions of patients with asthma and COPD around the world.”
ultrasonic nebuliser set to revolutionise the COPD and asthma devices market
Pocket–size or small ultrasonic nebulisers applying a novel nozzle that can enhance inhalers are witnessing higher demand. Industry experts believe that inhalation has opened new routes for the non-invasive drug delivery techniques, both in local as well as systematic applications. Besides this, control over the particle size and output is playing a critical part in ensuring the efficiency and effectiveness of the expensive drug delivery, which has caught the attention of various scientists and researchers.
A group of innovators from the “Department of Electrical Engineering and Computer Science” at the reputed University of California has invented novel equipment for inhalation drug delivery, which fulfils the requirements unmet by existing commercial devices. This is a clear indication that the future of the COPD and asthma devices market will remain robust in the years to come.